**UPDATE** Since this episode was recorded, Takeda announced the results of the phase 3 soticlestat trials, which did not meet their primary endpoints.We welcome Dr. Toshiya Nishi and Jason Tardio from Ovid Therapeutics. Dr. Nishi, with over 20 years of experience in drug discovery, discusses his role in the development of soticlestat and ongoing research on KCC2 activators for neurological disorders. Jason Tardio, Ovid's COO, shares insights on the company's focus on rare neurological disorders, including epilepsy, and its strategic initiatives for advancing treatments. Listen to their inspiring journey from the inception of Ovid Therapeutics to its current breakthroughs, and their perspectives on fostering a quality-driven and risk-tolerant culture in drug development.https://ovidrx.com/00:00 Introduction and Welcome00:40 Meet the Guests: Dr. Toshiya Nishi and Jason Tardia02:04 The Journey of Ovid Therapeutics03:58 Discovering Saticklistat: A Serendipitous Breakthrough08:35 Strategic Initiatives and Future Directions13:48 Collaboration and Culture at Ovid Therapeutics17:38 Ensuring Quality in Drug Development21:50 Personal Insights and Closing Remarks24:07 Conclusion and FarewellQualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Ver todos los episodios